Executive Leadership

Executive Leadership

Dr. Behzad Aghazadeh, Executive Chairman of the Board of Directors

Dr. Behzad Aghazadeh has served as Chairman of our Board of Directors since March 2017 and brings more than 20 years of experience in the biopharmaceutical industry, across various disciplines. The majority of Behzad’s career has been spent in healthcare investing, and he currently serves as Managing Partner and Portfolio Manager of Avoro Capital Advisors, LLC, an SEC registered investment manager. Behzad began his career in healthcare as a research scientist, later joining Booz Allen (now a unit of PricewaterhouseCoopers) as a management consultant, where he led major strategic and operational initiatives for companies in the pharmaceutical and biotechnology industries.

Dr. Aghazadeh holds a Masters in Physics from Ludwig-Maximilians University and a Ph.D. in Biochemistry & Biophysics from Cornell University.

Year Joined: 2017

Mr. Scott Canute, Executive Director of the Board of Directors

Mr. Scott Canute joined the Immunomedics board in 2017. Mr. Canute has more than 34 years of experience in the biopharmaceutical industry, previously serving as President of Global Manufacturing and Corporate Operations of Genzyme Corporation from 2010 until 2011, where he led a major turnaround in manufacturing in order to ensure the on-going supply of life-saving products that were in short supply and developed and implemented a comprehensive manufacturing strategy including a revamped global governance system. Prior to joining Genzyme, Mr. Canute spent 25 years at Eli Lilly and Company, where he served as President, Global Manufacturing Operations from 2004 until 2007. During his tenure at Eli Lilly, Mr. Canute directed all manufacturing and supply chain activities for the company’s global operations, which spanned 24 international manufacturing sites and 80+ contract manufacturing operations and managed a $3.7 billion budget.
Mr. Canute currently serves on the Board of Directors for Akebia Therapeutics, Inc., a biopharmaceutical company focused on kidney disease through the biology of hypoxia-inducible factor (HIF); Flexion Therapeutics, Inc., Proteon Therapeutics, Inc., and Oncobiologics, Inc. He previously served as a Director for Allocure Inc. Mr. Canute has also served as a member of the Board of Directors of the National Association of Manufacturers, the Indiana Manufacturers Association and the Tauber Manufacturing Institute-University of Michigan.

Mr. Canute holds a B.S. Chemical Engineering degree from the University of Michigan and an M.B.A. from Harvard Business School.

Year Joined: 2017

Usama Malik
Usama Malik, Chief Financial Officer, Chief Business Officer

Usama has over 25 years of experience in the technology, telecoms, and healthcare industries in key leadership roles ranging from corporate strategy, mergers and acquisitions, venture investing, product development, and operational management. He has worked on large-scale transformations across Fortune 500 companies, while helping to scale and grow numerous venture-backed and mid-sized organizations. He has lead key strategic efforts to bolster company balance sheets, take out costs, generate new revenue streams, raise capital, and lead multibillion dollar M&A transactions.

Usama holds a B.Sc, Electrical Engineering degree from University of Maryland at College Park and an M.B.A. Finance, Strategy, Entrepreneurship from INSEAD.

Year Joined: 2017

Brendan Delaney, Chief Commercial Officer

Brendan joined Immunomedics as Chief Commercial officer in November 2017. He has more than 22 years of global pharmaceutical and biotechnology experience, most recently serving as Vice President of U.S. Commercial Hematology-Oncology at Celgene Corporation. Brendan has led several successful product launches for blockbuster brands across both oncology and hematology. His deep commercial background and proven leadership will help drive Immunomedics to become a global oncology leader.

Brendan holds a B.S. Biological Sciences degree from Rutgers University and an M.B.A. Finance degree from The Stern School of Business at NYU.

Year Joined: 2017

Dr. Morris
Dr. Morris Rosenberg, Chief Technology Officer

Dr. Rosenberg is a highly experienced biotechnology veteran with over 30 years’ experience in the development of therapeutic agents to treat a variety of human diseases. As a scientist, engineer and executive, he has played a key role in the development of several important commercially approved therapeutics.

Dr. Rosenberg holds a B.S. in Biology, B.S., M.S. and D.Sc. in Chemical Engineering from Washington University in St. Louis.

Year Joined: 2018

Kurt Andrews
Kurt Andrews, Chief Human Resources Officer

Kurt has 25 years of human resources experience, principally in the Life Sciences and Biotechnology industries.

Kurt holds a B.A., in Liberal Arts and Sciences degree, and an M.A., in Labor and Industrial Relations degree both from University of Illinois at Urbana-Champaign

Year Joined: 2018

Jared Freedberg, General Counsel and Corporate Secretary

Jared oversees all aspects of Immunomedics’ Legal, Compliance and Intellectual Property functions. Jared brings more than 18 years of in-house executive legal experience in both the pharmaceuticals and pharma services industries, supporting the development and commercialization of a wide variety of products in numerous indication areas.

Jared holds a J.D degree from Duke University School of Law and a B.A degree from the University of Pennsylvania.

Year Joined: 2018

Bryan Ball, Chief Quality Officer

Bryan joined Immunomedics in February 2019 bringing more than 23 years of experience in Quality Operations, Systems, and Compliance in the Pharmaceutical, Biopharmaceutical and Medical Device industries. Prior to joining Immunomedics, Bryan was the Senior Vice President of Global Quality and EHS for Mallinckrodt Pharmaceuticals. Prior to Mallinckrodt, Bryan was the Vice President of Quality and Regulatory at Ben Venue Laboratories, a Boehringer-Ingelheim company.

Bryan holds a B.S. Biology degree from Central Michigan University, an M.S. Cellular and Molecular Biology degree from University of North Carolina at Charlotte, and an MBA, Finance degree from Westminster College.

Year Joined: 2019